CD33*CD3 BsAb for Acute Myeloid Leukemia

Phase 1

Waitlist Available

Led By Jessica Pollard, MD

Research Sponsored by Y-mAbs Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 52 weeks

Awards & highlights

Study Summary

This trial is testing a new antibody drug to treat relapsed or refractory acute myeloid leukemia in pediatric patients.

Eligible Conditions

Acute Myeloid Leukemia, Childhood

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 52 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~52 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Occurrence of Adverse Events

Occurrence of dose limiting toxicities (DLTs)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Subcutaneous administration of CD33*CD3 BsAb up to 12 cyclesExperimental Treatment1 Intervention

Subcutaneous administration of CD33*CD3 BsAb up to 12 cycles

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Children's Oncology GroupNETWORK

456 Previous Clinical Trials

239,783 Total Patients Enrolled

Y-mAbs TherapeuticsLead Sponsor

25 Previous Clinical Trials

1,554 Total Patients Enrolled

Jessica Pollard, MDPrincipal InvestigatorDana-Farber Cancer Institute

~1 spots leftby May 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.